Categories Navigation

Asset Publisher

null HIV unit
Hospital San Pedro (Logroño)


Our Infectious Disease Department is integrated in the Spanish AIDS Research Network (RIS). Our work aims at clinical and epidemiological research, and our collaborative research in clinical trials and other well conducted studies. Our lines of research are the following:

  • RIS Cohort (CoRIS): Our group collaborates in the inclusion and follow-up of patients, having a special interest in aging, immune response and comorbidities.
  • Cohort of patients infected by vertical transmission (CoRIS-Pe): Our group collaborates in the inclusion and follow-up of patients.
  • Clinical trials: Our group collaborates in the inclusion and follow-up of patients.

Our group collaborates actively with Dr. Santiago Moreno from Ramón y Cajal University Hospital (Madrid) and Dr. Julia del Amo from the National Center for Epidemiology, ISCIII (Madrid).

Related Assets


José Ramón Blanco
Laura Pérez

Related Assets

Related Assets


  • Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. 
    Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.  J Acquir Immune Defic Syndr. 2017;76(3):311-318. 
  • Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients. 
    Blanco JR, Jarrin I, Pérez-Elías MJ, Gutiérrez F, Hernández-Quero J, Portilla J, Dalmau D, Moreno S, Hernando V; CoRIS.  Antivir Ther. 2017;22(1):21-29. 
  • Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity. 
    Pérez-Matute P, Pichel JG, Iñiguez M, Recio-Fernández E, Pérez-Martínez L, Torrens R, Blanco JR, Oteo JA.  Antivir Ther. 2017;22(2):163-168. 
  • CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy. 
    Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masiá M, Berenguer J, Portilla J, Viladés C, Martínez E, Blanco JR;  HIV Med. 2016;17(9):653-61. 
  • Off-label use of maraviroc in clinical practice. 
    Blanco JR, Ochoa-Callejero L.  Expert Rev Anti Infect Ther. 2016;14(1):5-8. 
  • Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy. 
    Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F, Moreno S; CoRIS-Biobanco.  J Acquir Immune Defic Syndr. 2015;68(1):21-9. 
  • Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). 
    Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, Ochoa-Callejero L, Oteo JA, Blanco JR.  J Antimicrob Chemother. 2014;69(7):1903-10. 
  • Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. 
    Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, Blanco JR.  PLoS One. 2013;8(1):e53992. 
  • Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot study. 
    Pérez-Matute P, Pérez-Martínez L, Blanco JR, Ibarra V, Metola L, Sanz M, Hernando L, Martínez S, Ramírez A, Ramalle-Gomara E, Oteo JA.  J Int AIDS Soc. 2013;16:18609. 
  • Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. 
    Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA.  Oxid Med Cell Longev. 2013;2013:493413. 

Related Assets